252 related articles for article (PubMed ID: 25889218)
1. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
[TBL] [Abstract][Full Text] [Related]
2. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice.
Asselin CY; Lam A; Cheung DYC; Eekhoudt CR; Zhu A; Mittal I; Mayba A; Solati Z; Edel A; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Pierce GN; Niraula S; Jassal DS
J Nutr; 2020 Sep; 150(9):2353-2363. PubMed ID: 32510147
[TBL] [Abstract][Full Text] [Related]
3. The Cardioprotective Role of N-Acetyl Cysteine Amide in the Prevention of Doxorubicin and Trastuzumab-Mediated Cardiac Dysfunction.
Goyal V; Bews H; Cheung D; Premecz S; Mandal S; Shaikh B; Best R; Bhindi R; Chaudhary R; Ravandi A; Thliveris J; Singal PK; Niraula S; Jassal DS
Can J Cardiol; 2016 Dec; 32(12):1513-1519. PubMed ID: 27650929
[TBL] [Abstract][Full Text] [Related]
4. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Mozolevska V; Schwartz A; Cheung D; Goyal V; Shaikh B; Dingman B; Kim E; Mittal I; Asselin CY; Edel A; Ravandi A; Thliveris J; Singal PK; Czaykowski P; Jassal DS
Am J Physiol Heart Circ Physiol; 2019 Mar; 316(3):H446-H458. PubMed ID: 30499710
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and trastuzumab regimen induces biventricular failure in mice.
Milano G; Raucci A; Scopece A; Daniele R; Guerrini U; Sironi L; Cardinale D; Capogrossi MC; Pompilio G
J Am Soc Echocardiogr; 2014 May; 27(5):568-79. PubMed ID: 24534652
[TBL] [Abstract][Full Text] [Related]
6. Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice.
Eekhoudt CR; Bortoluzzi T; Varghese SS; Cheung DYC; Christie S; Eastman S; Mittal I; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Jassal DS
Curr Oncol; 2022 Apr; 29(5):2941-2953. PubMed ID: 35621631
[TBL] [Abstract][Full Text] [Related]
7. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity.
Walker JR; Sharma A; Lytwyn M; Bohonis S; Thliveris J; Singal PK; Jassal DS
J Am Soc Echocardiogr; 2011 Jun; 24(6):699-705. PubMed ID: 21353471
[TBL] [Abstract][Full Text] [Related]
8. Congenital absence of nitric oxide synthase 3 potentiates cardiac dysfunction and reduces survival in doxorubicin- and trastuzumab-mediated cardiomyopathy.
Zeglinski M; Premecz S; Lerner J; Wtorek P; Dasilva M; Hasanally D; Chaudhary R; Sharma A; Thliveris J; Ravandi A; Singal PK; Jassal DS
Can J Cardiol; 2014 Mar; 30(3):359-67. PubMed ID: 24484915
[TBL] [Abstract][Full Text] [Related]
9. Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity.
Guenancia C; Hachet O; Aboutabl M; Li N; Rigal E; Cottin Y; Rochette L; Vergely C
Cancer Chemother Pharmacol; 2016 Apr; 77(4):777-85. PubMed ID: 26914236
[TBL] [Abstract][Full Text] [Related]
10. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D
Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737
[TBL] [Abstract][Full Text] [Related]
11. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity.
Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G
Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
14. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy.
Jassal DS; Han SY; Hans C; Sharma A; Fang T; Ahmadie R; Lytwyn M; Walker JR; Bhalla RS; Czarnecki A; Moussa T; Singal PK
J Am Soc Echocardiogr; 2009 Apr; 22(4):418-24. PubMed ID: 19269133
[TBL] [Abstract][Full Text] [Related]
15. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
[TBL] [Abstract][Full Text] [Related]
16. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Oronsky B; Ao-Ieong ESY; Yalcin O; Carter CA; Cabrales P
Mol Pharm; 2019 Jul; 16(7):2929-2934. PubMed ID: 31038318
[TBL] [Abstract][Full Text] [Related]
18. Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor.
Thomas CM; Yong QC; Seqqat R; Chandel N; Feldman DL; Baker KM; Kumar R
Clin Sci (Lond); 2013 Apr; 124(8):529-41. PubMed ID: 23116220
[TBL] [Abstract][Full Text] [Related]
19. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
20. Small benefits in trastuzumab-related cardiotoxicity.
Das M
Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
[No Abstract] [Full Text] [Related]
[Next] [New Search]
